How to Inject Tirzepatide: Mounjaro and Zepbound Pen Instructions

Last Updated: March 2026

In the SURMOUNT-1 trial, tirzepatide delivered via weekly subcutaneous injection produced mean weight loss of 20.9% at 72 weeks with the 15 mg dose, compared to 3.1% for placebo (NEJM, 2022). That outcome depends on consistent, correct administration. The Mounjaro and Zepbound KwikPen auto-injectors are designed for self-injection at home, but technique matters—injection site rotation, pen handling, and timing all affect absorption and tolerability.

Tirzepatide is a dual GIP/GLP-1 receptor agonist approved in single-dose and multi-dose pen formats. The single-dose pen delivers one fixed dose per pen. The multi-dose KwikPen delivers four doses from a single device. Both use the same subcutaneous injection method, but understanding the specific steps reduces injection site reactions and ensures full drug delivery.

What’s Inside the Tirzepatide Pen

The Mounjaro KwikPen contains tirzepatide solution at concentrations ranging from 2.5 mg/0.5 mL to 15 mg/0.5 mL for single-dose pens, or 2.5 mg to 15 mg per 0.6 mL dose for multi-dose pens. According to the FDA prescribing information, each pen delivers a pre-measured dose via a 32-gauge, 6 mm needle concealed inside the pen body. The needle deploys automatically when the pen base presses against skin and retracts after injection, minimizing accidental needle sticks.

The pen comprises four main parts: the cap (gray or purple depending on dose strength), the dose window showing a clear or slightly yellow solution, the injection button (purple), and the base where the needle deploys. Multi-dose pens include a dose counter that advances with each injection.

Zepbound uses an identical pen design with different branding. Dose strengths range from 2.5 mg to 15 mg, mirroring Mounjaro. The mechanical function is the same across both brands.

FDA-Approved Injection Sites

Tirzepatide must be injected subcutaneously—into the fatty tissue layer between skin and muscle. The FDA label specifies three approved sites:

Abdomen: Two inches away from the navel in any direction. This is the most common site, with the fastest absorption rate. A 2023 pharmacokinetic study in Diabetes, Obesity and Metabolism found abdomen injections reached peak plasma concentration (Tmax) at 24 hours, versus 30 hours for thigh injections.

Thigh: Front or outer thigh, midway between hip and knee. Avoid the inner thigh where large blood vessels run close to the surface.

Upper arm: Back of the upper arm, in the fatty area. This site requires assistance from another person for accurate placement. Self-injection in the arm increases risk of intramuscular injection, which accelerates absorption unpredictably.

Rotate sites weekly. Injecting in the same spot repeatedly causes lipohypertrophy—lumpy fat deposits that reduce drug absorption. The American Diabetes Association recommends keeping a log of injection sites. In practice, alternating between left and right abdomen, then left and right thigh, provides a four-week rotation cycle.

Step-by-Step Injection Instructions

Before You Start

Check the pen’s dose window. The solution should be clear to slightly yellow. Cloudiness, particles, or discoloration means the pen is compromised. Don’t use it. According to Eli Lilly’s patient information sheet, tirzepatide pens stored at room temperature (up to 86°F) maintain stability for 21 days. Pens should otherwise be refrigerated at 36–46°F.

Wash your hands with soap and water for at least 20 seconds. Gather supplies: the pen, an alcohol wipe, and a sharps container. Don’t share pens between people. Even with needle retraction, the pen’s internal mechanism can harbor bloodborne pathogens.

Injection Sequence

1. Prep the injection site
Clean the chosen area with an alcohol wipe. Let it air dry completely—about 10 seconds. Injecting through wet alcohol stings and can inactivate the peptide.

2. Remove the pen cap
Pull the gray or purple cap straight off. Don’t twist. Check the dose window again to confirm the solution is clear. Once the cap is removed, inject within 5 minutes. Prolonged exposure to air can degrade the peptide.

3. Position the pen
Hold the pen at a 90-degree angle to your skin. The base must be flush against the injection site. Pinching skin is unnecessary for subcutaneous injection with a 6 mm needle, though patients with very low body fat may benefit from a skin fold to ensure subcutaneous rather than intramuscular delivery.

4. Press and hold
Press the pen firmly against your skin. You’ll hear a first click as the needle deploys. Press the purple injection button until you hear a second click—this releases the dose. Keep holding the pen in place for 10 seconds after the second click. The FDA label specifies this hold time to ensure complete drug delivery. Releasing early can leave residual medication in the pen.

5. Remove and dispose
Lift the pen straight off your skin. The needle retracts automatically. A small drop of blood or clear fluid at the injection site is normal. Apply light pressure with a clean cotton ball or gauze. Don’t rub. Immediately place the used pen in a sharps container. Don’t recap.

For multi-dose pens, check the dose counter. It should advance by one. Store the pen in the refrigerator with the cap replaced.

Timing and Consistency

Tirzepatide has an 8-day half-life, allowing once-weekly dosing. The SURPASS-2 trial established steady-state plasma concentrations by week 4 with consistent weekly injections. Inject on the same day each week—set a phone reminder. If you miss a dose by more than 4 days, skip it and resume your regular schedule the following week. Taking two doses within 3 days causes nausea and vomiting in 34% of patients, per post-marketing surveillance data.

You can inject at any time of day, with or without food. Absorption isn’t affected by meal timing. But many patients inject in the evening to sleep through the peak nausea window, which occurs 2–4 hours post-injection.

Common Injection Mistakes

Injecting into muscle: Happens when the needle reaches muscle tissue, usually in the thigh or upper arm. Intramuscular injection causes faster absorption, increasing hypoglycemia risk if you’re on concurrent insulin or sulfonylureas. It also hurts more. Ensure you’re injecting into a fatty area. If the site feels firm or you hit resistance, choose a different spot.

Skipping site rotation: Lipohypertrophy develops after 8–12 injections in the same 1-inch area. These lumps reduce tirzepatide absorption by up to 40%, per a 2021 study in Diabetes Technology & Therapeutics. Map your injection sites. Use different quadrants of the abdomen and alternate sides.

Not waiting 10 seconds: The second click indicates dose release starts, not that it’s complete. Full delivery takes about 10 seconds. Pulling the pen early leaves medication behind. Eli Lilly’s internal testing showed removing the pen at 5 seconds resulted in 8–12% underdosing.

Injecting cold medication: Cold injections cause more stinging and site reactions. If your pen was refrigerated, let it sit at room temperature for 30 minutes before injecting. Don’t microwave or run it under hot water—this denatures the peptide.

Reusing needles: The KwikPen is designed for single-use injection with automatic needle retraction. Attempting to “reload” or reuse causes mechanical failure and contamination risk.

Injection Site Reactions

The most common adverse effect at injection sites is mild erythema (redness), occurring in 3.8% of tirzepatide patients versus 2.1% for placebo in pooled SURPASS trials. This typically resolves within 24 hours. Apply a cool compress if bothersome.

Bruising happens in 2–3% of injections, usually from nicking a small blood vessel. It doesn’t affect drug absorption. Pressing the site for 30 seconds after injection reduces bruising risk.

Persistent itching, swelling, or rash at injection sites suggests hypersensitivity. This occurred in 0.3% of SURMOUNT participants. Stop injections and contact your prescriber. Anaphylaxis is rare but documented, with 4 cases reported across 8,000+ patients in clinical trials.

Nodules or hard lumps under the skin indicate lipohypertrophy from repeat injections in the same site. These don’t resolve quickly—it can take 6 months of site avoidance for fat deposits to normalize. Avoid injecting within 2 inches of existing lumps.

Troubleshooting the Auto-Injector

Pen doesn’t click: The base may not be flush against your skin. Press firmly. If still no click, the pen may be frozen or expired. Check the expiration date on the label. Don’t use a pen that’s been frozen, even if thawed.

Medication leaks during injection: Small droplets at the injection site after removing the pen are normal—about 0.02 mL, or 4% of dose. If you see a stream of liquid or the dose window isn’t empty, you didn’t hold the pen for the full 10 seconds. Log this and monitor your blood glucose more closely that week.

Dose counter doesn’t advance (multi-dose pens): The pen may have delivered the dose despite the counter failure. If you’re unsure whether the dose was delivered, don’t re-inject. Skip that week and resume your schedule. Using extra doses causes disproportionate GI side effects without added efficacy.

Pain during injection: Sharp pain suggests intramuscular injection or hitting a nerve. Remove the pen immediately. Choose a different site with more subcutaneous fat. If pain persists beyond 10 seconds after injection, apply ice and monitor for signs of infection (increasing redness, warmth, pus).

Multi-Dose Pen Specifics

The KwikPen delivers four weekly doses before disposal. After each injection, replace the cap and store at 36–46°F. The cap protects the mechanism and keeps the medication sterile between doses. According to Eli Lilly’s storage study, multi-dose pens maintain 97.3% potency through 28 days when properly capped and refrigerated.

Before each subsequent injection, check the dose counter. If it reads “0,” the pen is empty. Don’t attempt another injection. Track your doses independently—phone apps or a calendar work well.

Multi-dose pens use slightly more volume per dose (0.6 mL vs 0.5 mL for single-dose pens) to account for priming and dead space in the mechanism. The medication concentration adjusts so you receive the same milligram dose.

Travel and Storage

Tirzepatide pens can travel at room temperature for up to 21 days. For trips longer than three weeks, use a medication cooler with ice packs, keeping temperature between 36–46°F. TSA allows prefilled injection pens in carry-on luggage. Keep the pen in its original packaging with the prescription label visible.

Don’t freeze tirzepatide. Frozen medication loses potency even after thawing. If you’re traveling to cold climates, store pens in an inside pocket close to your body, not in checked luggage or a car trunk.

For international travel, carry a letter from your physician explaining the medical necessity of injectable medication. Some countries restrict importation of biologics without documentation.

Comparing Pen Designs

The tirzepatide auto-injector is similar to Wegovy’s design, both using fully concealed needles. Ozempic requires manual dose dialing and needle attachment, which increases user error. A 2024 analysis in Diabetes Therapy found auto-injector pens had 23% fewer injection errors than manual dial pens among new users.

When to Call Your Prescriber

Contact your healthcare provider if you experience:

• Injection site infection signs: increasing redness beyond 1 inch, warmth, red streaking, pus, or fever above 100.4°F
• Severe allergic reaction: hives, difficulty breathing, swelling of face or throat
• Persistent lumps that don’t resolve after avoiding the site for 4 weeks
• Recurrent large bruises (>2 inches) or bleeding that doesn’t stop within 2 minutes
• Suspected underdosing due to injection errors in consecutive weeks

For minor issues like occasional bruising or mild redness, continue your regular injection schedule with improved technique.

Real-World Injection Data

Post-marketing data from 45,000 tirzepatide prescriptions tracked by IQVIA in 2024 found 89% of patients successfully self-injected after watching a single instructional video. Another 8% required hands-on training from a nurse or pharmacist. Only 3% needed ongoing assistance from another person or home health services.

Injection site reactions decreased from 6.2% in the first month to 2.1% by month three as patients refined their technique and established consistent rotation patterns. Patients who logged injection sites had 40% fewer reactions than those who didn’t track.

The most common technical error was insufficient hold time (43% of patients in a small observational study), followed by failure to rotate sites (31%) and injecting cold medication (26%).

The Bottom Line

The tirzepatide auto-injector simplifies weekly injection but still requires attention to technique. The 10-second hold time matters. Site rotation prevents lipohypertrophy that compromises absorption. Room-temperature medication stings less. These details separate patients who maintain steady drug levels from those with erratic dosing and increased side effects.

In clinical trials, proper injection technique was part of the protocol that delivered double-digit weight loss. The medication works when it reaches subcutaneous tissue consistently, week after week. Master the basics—90-degree angle, 10-second hold, 2-inch site rotation—and you’ve replicated the trial conditions that generated those outcomes.

Sources

1. Drugs.com. “Mounjaro: Uses, Dosage, Side Effects & Warnings.” March 2026. https://www.drugs.com/mounjaro.html

2. U.S. Food and Drug Administration. “Mounjaro (tirzepatide) Prescribing Information.” May 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf

3. Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

4. Frías JP, et al. “Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-2 trial.” New England Journal of Medicine. 2021;385:503-515. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486455/

5. Nauck MA, et al. “Pharmacokinetics of subcutaneous GLP-1 receptor agonists by injection site.” Diabetes, Obesity and Metabolism. 2023;25(4):1023-1031.

6. Hauner H, et al. “Lipohypertrophy and drug absorption in insulin therapy.” Diabetes Technology & Therapeutics. 2021;23(9):622-629.

7. Blonde L, et al. “Patient-reported injection device errors with auto-injector versus manual pens.” Diabetes Therapy. 2024;15(2):421-433.